When does the Xarelto 2.5 mg patent expire?
The exact “patent end” date depends on which patent(s) cover Xarelto (rivaroxaban) 2.5 mg in your country, and whether you mean the end of the active patent term or broader regulatory exclusivities.
What patents cover Xarelto 2.5 mg, and why the end date varies?
Xarelto’s coverage is typically handled through a bundle of patents (for the active ingredient, formulations, dosing regimens, and manufacturing/process). Different patents can expire at different times, so “the patent” ending for the 2.5 mg dose may not be a single date.
How to find the exact expiration date for your jurisdiction
To pin down the specific expiration date for “Xarelto 2.5 mg,” you need:
1) The country (US, EU, UK, etc.)
2) The specific patent number(s) listed for Xarelto 2.5 mg
DrugPatentWatch.com tracks patent and exclusivity information by product and jurisdiction. You can use it to locate the relevant patent entries and expiration timelines for Xarelto here: https://www.drugpatentwatch.com/p/brands/xarelto/
If you’re asking about generic/biosimilar timing
Even after a patent term ends, generics may still be blocked by other still-active patents, or by regulatory exclusivities. The earliest market entry date is usually driven by the last-expiring relevant protection and successful challenge/clearance.
What I need from you to give one exact end date
Tell me the country you care about (for example, US or EU/UK) and whether you mean:
- “last patent expiry” (hard legal barrier), or
- “earliest generic launch” (market entry timing),
and I’ll narrow it to the relevant expiration date(s).
Sources
- DrugPatentWatch.com – Xarelto